The panelists discuss the Affordable Care Act (ACA) and what the effect of the legislation has been in the 5 years since it was passed. Austin Frakt, PhD, started off the conversation by highlighting issues of coverage and access. He noted that while the rate of insurance coverage has increased across the board, there is huge variation as a result of incomplete Medicaid expansion and incomplete engagement with the health insurance marketplace. As a result, the country hasn’t reached what might be considered the “right rate” of insurance coverage.
“We’re not really having a conversation about what to do next about that, because still haven’t gotten over, ‘Is the ACA communism or is it a great thing’ kind of debate,” Dr Frakt said.
In the aftermath of the ACA, there has been a lot of talk about how many people are insured and not enough on what level of insurance they have, Margaret E. O’Kane said. While she is a proponent of value-based insurance design, she recognizes that it’s easier to simply set a high deductible. Unfortunately, doing so puts barriers to appropriate care, she said.
Leah Binder raised the issue of the impact the ACA has had on employers. During the first 2 years after implementation, employers were simply trying to figure out how to comply with the law. But while they are frustrated by emerging regulations that change the rules on them, they have been interested in the movement toward value that the ACA has brought.
Although the ACA has been driving toward payment and delivery system reforms that should impact quality, and Matt Salo believes they will eventually lead to better quality, he doesn’t know if that has been demonstrated just yet. But Binder and O’Kane pointed out some measures, such as the complication rate in diabetes care and safety in hospitals, that show dramatic improvements are already taking place.
Looking forward with the ACA, even though it has beaten 2 legal challenges at the Supreme Court level, there is a new lawsuit making its way through the courts that questions the payments the administrator is giving insurers even though Congress never appropriated funds.
Industry Experts Tackle Specialty Drug Access Challenges for Employer Benefit Plans
May 2nd 2024Representatives from ICON plc and Symphony Health joined forces as AXS24 to discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More